Boston Scientific Production Of NIR-On-Ranger Stent With SOX On Hold
This article was originally published in The Gray Sheet
Boston Scientific is ramping up produciton of its NIR Primo coronary stent - also known as the NIR-On-Ranger without the SOX securing system - after temporarily ceasing production of the system with SOX due to a higher than anticipated balloon failure rate, the firm says.
You may also be interested in...
Boston Scientific will enroll approximately 400 patients in an ongoing clinical trial to support a PMA supplement for the firm's Taxus Liberty stent platform
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.